| |
Article Title |
Author(s) |
Pages |
|
|
|
CME Accreditation Page and Author Disclosure
|
|
iii
|
|
|
|
Forthcoming/Recent Issues
|
|
iv
|
|
|
|
Contributors
|
|
v-vi
|
|
|
|
Contents
|
|
vii-ix
|
|
|
|
Foreword
The one thing none of us can escape is “Father Time”! As a result, the fastest growing segment of neuroimaging is dementia. The current prevalence of dementia is anticipated to double every 20 years a...
|
Suresh K. Mukherji
|
xi
|
|
|
|
Preface
Dementia is a massive and increasing global problem, with the current prevalence anticipated to double every 20 years as people live longer. Neuroimaging in dementia is recommended by most clinical gu...
|
Alison D. Murray
|
xiii-xiv
|
|
|
|
Spatial Distribution and Secular Trends in the Epidemiology of Alzheimer's Disease
There are well-established differences in dementia incidence between communities and within communities over time. In part, these differences may be attributable to local improvements in dementia diag...
|
Lawrence J. Whalley
|
1-10
|
|
|
|
The Molecular Pathology of Alzheimer's Disease
Neurofibrillary pathology in Alzheimer's disease consists of paired helical filaments comprising tau protein. This pathology is correlated with dementia, but can appear in the first two decades of lif...
|
Charles R. Harrington
|
11-22
|
|
|
|
Clinical and Research Diagnostic Criteria for Alzheimer's Disease
In contrast with the previous criteria published in 1984 by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association,...
|
Marie Sarazin,
Leonardo Cruz de Souza,
Stéphane Lehéricy,
Bruno Dubois
|
23-32
|
|
|
|
Structural Neuroimaging in Aging and Alzheimer's Disease
The role of structural neuroimaging in the diagnosis of Alzheimer's disease (AD) is becoming increasingly important. As a consequence, a basic understanding of what are normal brain changes in aging i...
|
Meike W. Vernooij,
Marion Smits
|
33-55
|
|
|
|
Molecular Neuroimaging in Alzheimer's Disease
08 December 2011
This article reviews current amyloid positron emission tomography (PET) imaging with particular attention to Pittsburgh compound-B (PiB), the most extensively investigated and validated tracer. PiB sp...
|
Hiroshi Matsuda,
Etsuko Imabayashi
|
57-65
|
|
|
|
Neuroimaging of Dementia with Lewy Bodies
Dementia with Lewy bodies (DLB) is a relative newcomer to the field of late-life dementia. Although a diversity of imaging methodologies is now available for the study of dementia, these have been app...
|
John-Paul Taylor,
John O’Brien
|
67-81
|
|
|
|
Frontotemporal Lobar Degeneration: New Understanding Brings New Approaches
Frontotemporal dementia (FTD) describes a group of clinical syndromes united by underlying frontotemporal lobar degeneration (FTLD) pathology. The clinical syndromes associated with FTLD are heterogen...
|
Maria Carmela Tartaglia
|
83-97
|
|
|
|
Reserve, Brain Changes, and Decline
02 December 2011
Reserve refers to the brain's ability to cope with increasing damage. There is no direct measure of reserve, but it is commonly reflected in the literature by proxies such as brain volume, head size, ...
|
Roger T. Staff
|
99-105
|
|
|
|
The Clinical Value of Large Neuroimaging Data Sets in Alzheimer's Disease
19 December 2011
Rapid advances in neuroimaging and cyberinfrastructure technologies have brought explosive growth in the Web-based warehousing, availability, and accessibility of imaging data on a variety of neurodeg...
|
Arthur W. Toga
|
107-118
|
|
|
|
Index
|
|
119-121
|
|
